CRISPR Therapeutics AG

NASDAQ Global Market
Back to all articles
Slightly Bullish +15

Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) Director Sells ...

AI-generated analysis

📉 Director Ali Behbahani sold 13,679 shares of CRSP on September 17th for a total value of $780,934.11.

📊 The company reported Q2 earnings of -$0.94 EPS on revenue of $10.18 million as of June 30th.

🏦 Capital International Investors increased its CRSP holdings by 4.3% in the fourth quarter to own 5,892,745 shares.

📈 Geode Capital Management LLC raised its stake by 5.0% in the fourth quarter, adding 108,053 shares.

🏛 Norges Bank and Swiss National Bank established or increased new positions in CRSP during recent quarters.

💰 The company's market cap stands at $5.64 billion with a debt-to-equity ratio of 0.34.

📉 Analysts forecast an average EPS of -$4.47 for the current fiscal year following Q2 results.

🎯 Morgan Stanley set a $60.00 price objective while Goldman Sachs issued a $55.00 target.

🔬 CRISPR Therapeutics' lead product Casgevy is approved in several markets for sickle cell disease and beta thalassemia.

Bullish Signals
  • Major institutional investors including Capital International Investors, Geode Capital Management LLC, Norges Bank, and Swiss National Bank increased or established new positions in the fourth quarter.
  • MarketBeat aggregates analyst ratings to a 'Moderate Buy' with an average price target of $67.94, suggesting potential upside from current levels.
  • The company's lead product Casgevy is approved in several markets for treating sickle cell disease and transfusion-dependent beta thalassemia.
Risk Factors
  • Director Ali Behbahani reduced his position by 45.12% through a significant sale of 13,679 shares on September 17th.
  • Analysts forecast continued losses with an average expected EPS of -$4.47 for the current fiscal year.
Full Analysis
CRISPR Therapeutics AG (NASDAQ:CRSP) director Ali Behbahani sold 13,679 shares on September 17th at an average price of $57.09, reducing his position by 45.12% to a remaining holding of 16,637 shares valued at approximately $949,806. This insider transaction was disclosed in a legal filing with the Securities & Exchange Commission. The company reported quarterly earnings for the quarter ended June 30th, posting a loss of $0.94 per share on revenue of $10.18 million. CRISPR Therapeutics has a market capitalization of $5.64 billion and trades with a price-to-earnings ratio of -12.25. Analysts forecast an average annual EPS of -$4.47 for the current fiscal year. Wall Street sentiment remains mixed, with Morgan Stanley maintaining an 'equal weight' rating at $60.00 and Goldman Sachs reiterating a 'neutral' stance at $55.00. However, MarketBeat aggregates analyst ratings to a 'Moderate Buy' with an average price target of $67.94. Institutional ownership is significant, with major funds like Capital International Investors and Geode Capital Management increasing their stakes in the fourth quarter.